SG11202104192TA - Combination of small molecule cd-47 inhibitors with other anti-cancer agents - Google Patents

Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Info

Publication number
SG11202104192TA
SG11202104192TA SG11202104192TA SG11202104192TA SG11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA SG 11202104192T A SG11202104192T A SG 11202104192TA
Authority
SG
Singapore
Prior art keywords
inhibitors
combination
small molecule
cancer agents
cancer
Prior art date
Application number
SG11202104192TA
Other languages
English (en)
Inventor
Muralidhara Ramachandra
Pottayil Govindan Nair Sasikumar
Girish Chandrappa Daginakatte
Kiran Aithal Balkudru
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of SG11202104192TA publication Critical patent/SG11202104192TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202104192TA 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents SG11202104192TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Publications (1)

Publication Number Publication Date
SG11202104192TA true SG11202104192TA (en) 2021-05-28

Family

ID=69159806

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104192TA SG11202104192TA (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Country Status (14)

Country Link
US (3) US11311517B2 (https=)
EP (1) EP3876931A1 (https=)
JP (2) JP7623279B2 (https=)
KR (1) KR20210088584A (https=)
CN (2) CN112930181B (https=)
AU (1) AU2019375193A1 (https=)
BR (1) BR112021008781A2 (https=)
CA (1) CA3118843A1 (https=)
EA (1) EA202190776A1 (https=)
IL (1) IL282972B2 (https=)
MX (2) MX2021005240A (https=)
PH (1) PH12021550832A1 (https=)
SG (1) SG11202104192TA (https=)
WO (1) WO2020095256A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
EP4291238A4 (en) * 2021-02-10 2024-10-09 Great Novel Therapeutics Biotech & Medicals Corporation PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING AN IMMUNE RESPONSE AGAINST CANCER
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
WO2025083628A1 (en) 2023-10-19 2025-04-24 Aurigene Oncology Limited Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
US20250339404A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672828A1 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
EP3267985A4 (en) 2015-03-10 2018-07-25 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
NZ734650A (en) * 2015-03-10 2023-07-28 Aurigene Oncology Ltd 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
DK3454879T3 (da) 2016-05-10 2022-03-14 Inst Nat Sante Rech Med Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft
WO2018047139A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
MY205585A (en) * 2016-10-20 2024-10-28 Aurigene Oncology Ltd Dual inhibitors of vista and pd-1 pathways
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
WO2019175799A2 (en) * 2018-03-14 2019-09-19 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds

Also Published As

Publication number Publication date
CA3118843A1 (en) 2020-05-14
IL282972B1 (en) 2025-02-01
CN112930181B (zh) 2025-05-13
IL282972A (en) 2021-06-30
EP3876931A1 (en) 2021-09-15
CN112930181A (zh) 2021-06-08
AU2019375193A1 (en) 2021-05-13
JP2022507025A (ja) 2022-01-18
US20250177358A1 (en) 2025-06-05
EA202190776A1 (ru) 2021-09-20
US20220241248A1 (en) 2022-08-04
JP2025063207A (ja) 2025-04-15
KR20210088584A (ko) 2021-07-14
US20200147054A1 (en) 2020-05-14
US12268670B2 (en) 2025-04-08
JP7623279B2 (ja) 2025-01-28
IL282972B2 (en) 2025-06-01
BR112021008781A2 (pt) 2021-08-03
MX2021005240A (es) 2021-06-18
US11311517B2 (en) 2022-04-26
MX2024006094A (es) 2024-05-30
WO2020095256A1 (en) 2020-05-14
PH12021550832A1 (en) 2021-10-04
CN120305258A (zh) 2025-07-15

Similar Documents

Publication Publication Date Title
SG11202104192TA (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
IL321844A (en) Menin–MLL interaction inhibitors
IL289754A (en) Piperidinylmethylpurinamines as nsd2 inhibitors and anticancer agents
IL275089A (en) Polycyclic substances as allosteric SHP2 inhibitors
IL261557A (en) Small molecule ire1-alpha inhibitors
ZA201904615B (en) Small molecule inhibitors of the jak family of kinases
IL254769A0 (en) Nitrobenzyl history of anticancer agents
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
EP4194530B8 (en) Use of lubricant compositions for direct injection engines
PL3512850T3 (pl) Inhibitory interakcji menina-mll
IL256393B (en) Polycyclic amide derivatives as cdk9 inhibitors
IL255310A0 (en) Thioether compounds as nitrification inhibitors
IL283433A (en) Small molecule inhibitors of ire1
EP3695635A4 (en) MITIGATION OF RISKS DURING HANDS-FREE INTERACTIONS
DK3240767T3 (da) Mikroindkapslede nitrifikationshæmmersammensætninger
IL281634A (en) Diacosocyclobutanylamino-3-hydroxy-picoline modified amide and its use as a CCR6 inhibitor
SI3573620T1 (sl) Sestavki za zdravljenje hipertenzije
IL276312B1 (en) Use of Alkoxypyrazoles as nitrification inhibitors
DK3137437T3 (da) Mikroindkapslet nitrifikationsinhibitorsammensætning
IL281949A (en) Small molecule menin inhibitors
ITUA20161994A1 (it) Uso degli inibitori ddx3 come agenti anti-iperproliferativi
EP3733206A4 (en) ANTI-CANCER AGENTS
PL3675894T3 (pl) Kompozycja do kontrolowanej stymulacji jajników
DK3595442T3 (da) Mikroindkapslede nitrifikationsinhibitorsammensætninger
HK40062928A (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents